The diabetes landscape is rapidly changing. Since the 2018 Diabetes Canada guidelines were published, new evidence has emerged, prompting an update to the chapter on pharmacologic management of adults with type 2 diabetes (T2D). The two pillars of diabetes management include achieving glycemic targets and providing cardiovascular and renal protection.
This program is designed to discuss the updated recommendations from Diabetes Canada regarding the pharmacologic management of adults with T2D. The goal is for all participants to be able to incorporate guideline recommendations into their practice to ensure effective T2D management.
This program is developed in collaboration with M3 (EU) Ltd.
Supported by an education grant from Novo Nordisk A/S.